Insulet price target raised to $236 from $234 at Canaccord

Canaccord raised the firm’s price target on Insulet to $236 from $234 and keeps a Buy rating on the shares. The firm said the company noted that new patient starts grew, and expects sequential acceleration from both Q2 to Q3, and Q3 to Q4. Insulet raised guidance, now expecting total company growth in the range of 16%-19%, inclusive of US Omnipod revenue growth and OUS growth.